INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Hims & Hers Health, Inc. of Class Action Lawsuit and Upcoming Deadlines - HIMS

Core Viewpoint - A class action lawsuit has been filed against Hims & Hers Health, Inc. concerning allegations of securities fraud and unlawful business practices [2][3]. Group 1: Lawsuit Details - The lawsuit involves claims that Hims & Hers and certain officers/directors engaged in securities fraud or other unlawful business practices [2]. - Investors who purchased Hims & Hers securities during the Class Period have until August 25, 2025, to request to be appointed as Lead Plaintiff [3]. Group 2: Partnership and Stock Impact - On April 29, 2025, Hims & Hers announced a collaboration with Novo Nordisk to sell a bundled offering of Wegovy® [3]. - On June 23, 2025, Novo Nordisk terminated its partnership with Hims & Hers, citing deceptive promotion and selling of illegitimate versions of Wegovy® that jeopardized patient safety [3]. - Following the termination announcement, Hims & Hers' stock price dropped by $22.24, or 34.63%, closing at $41.98 per share [3].